Compare Cigna Corp (CI) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs Okta, Inc. — how do they compare? Cigna Corp trades at $272.72 (market cap $73.56B), while Okta, Inc. trades at $150.35 (market cap $26.20B). The key difference: Cigna Corp is far larger — about 2.8× Okta, Inc.'s market cap, and Cigna Corp pays a 2.24% dividend while Okta, Inc. pays none. Which is the better fit depends on your goals.
| CI | OKTA | |
|---|---|---|
Market Cap | $73.56B | $26.20B |
Sector | Health | Technology |
52-Week High | $311.00 | $154.62 |
52-Week Low | $244.41 | $62.93 |
Enterprise Value | $98.27B | $24.03B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cigna (CI) trades at $282.49, up 2.63% with strong earnings beats in recent quarters. The stock shows bearish technical signals but benefits from low valuation ratios like a P/E of 11.68 and P/S of 0.27. Recent Q2 2026 results exceeded expectations, with EPS of $7.78 beating estimates, and the company raised its full-year guidance to at least $30.45 adjusted EPS, reflecting robust growth in health services and insurance segments.
The outlook is positive due to consistent earnings outperformance and raised guidance, though technical weakness and competitive pressures pose risks. Analyst consensus is strongly bullish with a $338.90 price target, indicating ~20% upside potential from current levels, supported by dividend payments and institutional accumulation.
OKTA trades at $148.32, up 3.35% today, near its recent high of $157.00. The stock shows bullish momentum with consistent earnings beats, including Q1 2026 EPS of $0.91 versus $0.853 expected. Revenue growth is robust, rising from $1.3B in 2022 to $2.6B in 2025, with net income turning positive at $28M. Technical indicators signal bullish trends, while analyst consensus is strongly positive with 72.55% buy ratings.
Outlook is favorable due to strong cybersecurity demand and AI-driven product launches, but risks include high valuation (P/E of 107.48) and competition. Upside potential exists if earnings growth continues, with a consensus price target of $127.96 suggesting caution relative to current price. Investors should monitor Q2 2026 results on August 26, 2026, for confirmation of profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
